474P - Effects of smoking habit in NSCLC with KRAS mutation in pathological stage I
| Date | 20 December 2015 |
| Event | ESMO Asia 2015 Congress |
| Session | Poster presentation 2 |
| Topics | Non-small-cell lung cancer Aetiology, epidemiology, screening and prevention Translational Research Basic Scientific Principles Basic Principles in the Management and Treatment (of cancer) |
| Presenter | Hiroaki Kuroda |
| Citation | Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532 |
| Authors |
H. Kuroda1, K. Seto2, T. Yoshida3, T. Mizuno3, N. Sakakura3, T. Hida3, Y. Yatabe4, Y. Sakao5
|
Abstract
Aim/Background
KRAS mutation plays important roles in the pathobiology of NSCLC and is well known to the resistance of EGFR inhibitors. KRAS mutation is strongly associated with smoking habit, but the non to light smoker having KRAS mutation rarely exist.
Methods
We conducted a retrospective study of 104 patients diagnosed as KRAS mutation compared to 217 patients with the diagnosis as Wild type in pathological stage I. The proportion of non to light smoker {smoking index (SI): 0 to 400} were 37.5 (39/104) in the patients with KRAS mutation.
Results
KRAS with more than 400 in SI showed a shorter survival than KRAS with non to light smoker or Wild type (p = 0.03 and p < 0.01). The maximum tumor size and mediastinal size on preoperative CT was equivalent between the difference of smoking habit in KRAS mutation. Preoperative CEA was 4.56-fold higher in KRAS with more than 400 in SI than those with non to light (p < 0.01).
Conclusions
Our results suggested that KRAS mutation showed the poor prognosis in spite of stage I NSCLC. However, non to light smoker might have the possibility of contribution to improve prognosis among them.
Clinical trial identification
Disclosure
All authors have declared no conflicts of interest.